GE Healthcare and Lantheus Phase III Clinical Trial Finds [18F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease
13.9.2022 15:05:00 EEST | Business Wire | Press release
GE Healthcare and Lantheus Holdings Inc (NASDAQ: LNTH) have announced that the recent Phase III clinical trial of their investigational radiotracer, [18F]flurpiridaz, has met its co-primary endpoints of exceeding a 60 percent threshold for both sensitivity and specificity for detecting Coronary Artery Disease (CAD). The findings, shared at the American Society of Nuclear Cardiology (ASNC) Congress, in Florida, U.S., also demonstrate [18F]flurpiridaz Positron Emission Tomography (PET) has higher diagnostic efficacy and image quality in patients with suspected CAD, compared with Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI), the predominant procedure used in nuclear cardiology today. SPECT MPI represents approximately 6 million procedures per year in the U.Si.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220913005138/en/
The Phase III Open-Label Study, which involved over 600 patients across sites in the U.S., Europe and Canada assessed the diagnostic efficacy of [18F]flurpiridaz in detecting CAD, the most common form of heart diseaseii and the leading cause of death globallyiii, with invasive coronary angiography as a standard of truth. More than 120 million people are affected by CAD globally each yeariv and in the U.S. alone, approximately 20 million adults have CAD, with nearly 383,000 deaths recorded in 2020v.
If approved, this investigational agent would offer the advantages of 18F, with broad available distribution and a half-life of almost two hours, removing the need for it to be manufactured in the immediate vicinity of the imaging department. This longer half-life could also make Flurpiridaz (18F) Injection suitable for exercise stress testing, which is not feasible with existing cardiac PET radiotracers.
Dr. Tim Bateman, MD, FACC, co-director of the Cardiovascular Radiologic Imaging Program at Saint Luke's Hospital, Missouri, US, shared: “These results are truly promising for the nuclear cardiology community and CAD patients. From ASNC’s inception, its leaders have laid out the specifications for an ideal myocardial perfusion tracer. In my view [18F]flurpiridaz could meet this goal, expanding how PET MPI can be used to image CAD patients moving forward.”
Dr. Francois Tranquart, MD, PhD, Global Head of Clinical Development for GE Healthcare Pharmaceutical Diagnostics, Research and Development, said: “The positive Phase III trial results are a key step towards future approval of Flurpiridaz (18F) Injection as a potential new cardiac PET agent which could improve the detection of coronary artery disease. This is another example of GE Healthcare investing in our portfolio of Molecular Imaging products to help improve diagnostic accuracy and patient outcomes.”
GE Healthcare has led the funding and development of [18F]flurpiridaz, and, if the imaging agent is approved, will have global commercialization rights. Lantheus has collaborated on the development and will also collaborate on potential commercialization through a joint steering committee. Lantheus is entitled to royalties based on commercial sales.
GE Healthcare’s Pharmaceutical Diagnostics unit is a global leader in imaging agents used to support around 100 million procedures per year globally, equivalent to three patients every second. Its Molecular Imaging portfolio combines an innovative pipeline with established proprietary products across cardiology, neurology and oncology.
About GE Healthcare:
GE Healthcare is the $17.7 billion healthcare business of GE (NYSE: GE). As a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator, GE Healthcare enables clinicians to make faster, more informed decisions through intelligent devices, data analytics, applications and services, supported by its Edison intelligence platform. With over 100 years of healthcare industry experience and around 48,000 employees globally, the company operates at the center of an ecosystem working toward precision health, digitizing healthcare, helping drive productivity and improve outcomes for patients, providers, health systems and researchers around the world.
Follow us on Facebook, LinkedIn, Twitter, and Insights for the latest news, or visit our website www.gehealthcare.com for more information.
About Lantheus
With more than 60 years of experience in delivering life-changing science, Lantheus is committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease. Lantheus is headquartered in Massachusetts and has offices in New Jersey, Canada and Sweden. For more information, visit www.lantheus.com.
###
i Data on File: AMR Market Guide 2021.
ii WHO Factsheet 2020. Cardiovascular diseases (CVDs). 11 June 2021.
iii Global Epidemiology of Ischemic Heart Disease: Results from the Global Burden of Disease Study. July 23 2020.
iv Global Epidemiology of Ischemic Heart Disease: Results from the Global Burden of Disease Study. July 23 2020.
v Centers for Disease Control and Prevention. Heart Disease Facts. Accessed July 15 2022.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220913005138/en/
Contact information
GE
Healthcare Media Contact:
Debbie Leven
Debbie.Leven@ge.com
+44 7785 456999
Lantheus Contacts:
Investors
Mark Kinarney
Vice President, Investor Relations
978-671-8842
ir@lantheus.com
Media
Melissa Downs
Senior Director, Corporate Communications
646-975-2533
media@lantheus.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Navan Unveils New Ways to Book, Expense, and Travel at Navigate Europe 202615.10.2026 17:30:00 EEST | Press release
Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, unveiled a new set of capabilities and product updates at Navigate Europe, its flagship customer conference. The updates bring Navan into more workplace tools, expand card issuing to new currencies, and simplify guest reimbursement, all while giving businesses greater visibility and control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015250476/en/ “Business never stands still. Our customers are constantly expanding and expecting more value, which is why we continue to innovate and elevate every part of the employee experience,” said Michael Riegel, Chief Customer Officer at Navan. “We’ve spent years building the global technology infrastructure and expertise to make travel and expense work better. These new capabilities will support more users in more ways than ever before, all from one connected platform that moves as fast as they do.”
FlightSafety International to Deliver New Embraer E190-E2 Full-Flight Simulator to Azul Brazilian Airlines15.10.2026 17:05:00 EEST | Press release
FlightSafety International Inc. (FSI), the global leader in aviation training and simulation technology, today announced an agreement with Azul Brazilian Airlines to design and manufacture a new Embraer E190-300 (E190-E2) Level D Full-Flight Simulator. Anticipated for delivery in late 2027, the simulator will expand Azul’s pilot training capabilities at its training center in Campinas, São Paulo, Brazil. “Our partnership with Azul reflects a shared commitment to advancing aviation training and safety,” said Michele Posey, Executive Vice President, Sales, FlightSafety International. “This new simulator will provide Azul pilots with a highly realistic training environment that supports the development of critical skills and prepares them for the demands of commercial flight operations.” “This new simulator represents another important investment in Azul’s operational excellence and long-term growth strategy. Expanding our training capabilities ensures that we continue to prepare our pilo
Andersen Global Deepens Private Client Tax Capabilities with KTA Tax15.10.2026 16:30:00 EEST | Press release
Andersen Global broadens its private client tax capabilities through a Collaboration Agreement with KTA Tax, a Dublin-based tax practice that has advised individuals and families for nearly three decades. KTA Tax has advised private clients and their families since 1997, combining the personal approach of a boutique practice with deep technical knowledge of Irish taxation. Its services span transaction and tax planning, estate planning, investments and pensions, cross-border matters, Revenue interventions, employment tax, and annual personal tax compliance. “We have remained focused on one thing: providing clear, thoughtful tax advice that reflects the individual circumstances of our clients and their families,” said Lisa Cantillon, CEO of KTA Tax. “Collaborating with Andersen Global is an important step for KTA Tax, giving us an opportunity to build on that foundation while extending the resources available to the clients we serve.” “Private client work demands an understanding of mor
Sysco Awards Partner of the Year Award to Grid Dynamics15.10.2026 16:15:00 EEST | Press release
Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (“Grid Dynamics”) today announced that Sysco, the global foodservice distribution leader, has named the company its Partner of the Year. The recognition honors Grid Dynamics’ approach and expertise in bringing AI into Sysco’s technology and business operations. Sysco is the global leader in foodservice distribution, generating $84.6 billion in sales for its fiscal year ended June 27, 2026, and serving approximately 670,000 customer locations across 10 countries. The partnership began in 2024 with Grid Dynamics teams working alongside Sysco across product search and discovery, digital commerce, and AI-first software development. Grid Dynamics delivered a range of projects that made everyday work easier for Sysco's associates, enhanced the customer experience, and generated measurable business value. “What makes this partnership work is how closely our teams operate together,” said Ragnarok Rocha, Vice President, Digital Commerce and Customer S
The Outcome Economy at Work – New Research From Vertage15.10.2026 16:01:00 EEST | Press release
Three in four enterprises (74%) define significant work around outcomes, but only 15% are ready to deliver it consistently, according to new global research from HR tech leader Vertage. These ‘outcome-ready’ enterprises report higher customer satisfaction (91% vs. 67%), stronger delivery of strategic goals (86% vs. 65%) and faster conversion of opportunities into value (85% vs. 64%). They also have a cultural edge: 69% of their employees understand their contribution and can adapt how they work, compared with 34% elsewhere. "AI adoption no longer separates strong businesses from the rest. Outcome readiness does," said Edzard Overbeek, Group CEO of Vertage. "The strongest businesses organize people, partners and AI around a clear result, and they keep human judgment at the center." The study, The Outcome Economy at Work, draws on 800 enterprise decision-makers and 1,200 workers across six markets, plus in-depth interviews with senior leaders. Its central finding is clear: outcome-based
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom